Joseph Wagner sees most cell-therapy companies offering little more than a bag of cells.
His company will give the bag a little direction.
Cell Targeting is developing technology that can point stem cell therapies to specific areas of the body. Among the many challenges in cell therapy is direction: not enough of the stem cells are getting to the tissues that needs treatment (…)
Currently a stem cell therapy can help different parts of the body. That attracts more customers, but doesn’t do much when the company wants to differentiate its product and charge a different price.
A stem cell therapy tweaked by
Reviewing the technology, business models, intellectual property, regulatory concerns, transplantation and immune rejection.
CD133 (Prominin) is widely used as a marker for the identification and isolation of neural precursor cells from normal brain or tumor tissue. However, the assumption that CD133 is expressed constitutively in neural precursor cells has not been examined.
In this study, we demonstrate that CD133 and a second marker CD15 are expressed heterogeneously in uniformly undifferentiated human neural stem (NS) cell cultures. After fractionation by flow cytometry, clonogenic tripotent cells are found in populations negative or positive for either marker. We further show that CD133 is down-regulated at the mRNA level in cells lacking CD133 immunoreactivity. Cell cycle
Spinal cord injuries, resulting in permanent disability or paralysis in most cases, account for around eleven thousand new cases in the US, annually. Due to the lack of effective treatment strategies, it is considered as the most devastating of all traumatic conditions. Now, a recent study published in the journal Stem Cells reports that activation of ependymal stem/progenitor cells from injured spinal cord (epSPCi), using endogenous stem cell-associated mechanisms, may aid in rescuing neurological function, thereby reversing paralysis associated with spinal cord injuries.
Scientists have now shown that skin cells can be coaxed to behave like muscle cells and muscle cells like skin cells.
The fickleness of the cells, and the relative ease with which they make the switch, provide a glimpse into the genetic reprogramming that must occur for a cell to become something it’s not.
“We’d all like to understand what happens inside the black box (cell),” said Helen Blau, professor and member of Stanford University‘s Stem Cell Biology and Regenerative Medicine Institute and co-author of a new study on the subject.
Harnessing these genetic makeovers will allow scientists to better